Printer Friendly

Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.

1. Introduction

B-cell prolymphocytic leukemia (B-PLL) is a rare lymphoid neoplasm constituting approximately 1% of all cases of lymphocytic leukemia [1]. The median age at diagnosis of BPLL is 69 years, and the condition has a similar distribution pattern among male and female patients, who typically present with B symptoms, marked lymphocytosis, massive splenomegaly, and minimal lymphadenopathy [2]. The diagnosis requires the presence of prolymphocytes, exceeding 55% of lymphoid cells in the peripheral blood [3]. However, distinguishing between B-PLL and chronic lymphocytic leukemia (CLL)--which has increased number of prolymphocytes and the blastoid variants of mantle cell lymphoma--solely on the basis of morphological assessments may be difficult, necessitating usage of immunophenotypic studies [3,4]. B-PLL cells strongly express the surface immunoglobulins, IgM+/-IgD, and various B-cell antigens (CD19, CD20, CD22, CD79a and CD79b, and FMC7). Positive CD5 and CD23 expressions are seen in only 20-30% and 10-20% of the cases, respectively [2].

Treatment strategies for B-PLL remain to be established. The largest clinical trial of B-PLL included only 14 patients treated with pentostatin, and all other studies are limited to case reports or series with lesser than 10 patients [5]. Therefore, in the absence of clinical trials, clinicians typically employ a CLL-like treatment approach. Combinations of rituximab with fludarabine or bendamustine together with an anthracycline (mitoxantrone or epirubicin) have been reported to show significant activity in B-PLL [6-8]. However, resistance to purine analog/alkylator based therapy is high among B-PLL patients, as more than half of these patients have TP53 abnormalities including del(17p) [3, 9,10]. Until recently, alemtuzumab was the only effective therapeutic option for these patients, despite being associated with high rates of infections and short-lived responses [11, 12]. Lately, ibrutinib or idelalisib combined with rituximab has shown the best treatment outcome (response rates, progression-free survival, and overall survival) in TP53disrupted CLL patients [13,14]. Nevertheless, little is known about the treatment outcome of these new drugs in B-PLL, as very few patients have received either ibrutinib or idelalisibrituximab [15,16].

Herein, we report, for the first time, the efficacy of sequential kinase inhibition therapy (idelalisib-rituximab/ibrutinib) followed by allo-HSCT, in a patient diagnosed with B-PLL.

2. Case Presentation

A 48-year-old man was admitted in July 2015 with complains of abdominal discomfort, progressive night sweats, and a 10-kg weight loss over a period of 6 months. A full blood count showed the following findings: white blood cell count, 622 x [10.sup.9]/L; hemoglobin (Hb) concentration, 80 g/L; platelet count, 83 x [10.sup.9]/L; and LDH, 378 IU/L. A peripheral blood film demonstrated marked lymphocytosis with variably sized lymphocytes having clumped chromatin and central nucleoli (Figure 1). Peripheral blood immunophenotyping demonstrated that the lymphocyte population was composed almost exclusively of monoclonal B cells (95% of the lymphoid cells) with the following immunophenotype: [CD19.sup.+], [CD20.sup.+], [CD79b.sup.+], [CD5.sup.+], [FMC7.sup.+], [CD23.sup.+/-], and [CD10.sup.-]. Fluorescent in situ hybridization (FISH) showed positive findings for del(17p) in 86% of the cells and negative findings for deletion of 11q, 13q, trisomy 12, and t(11; 14). A bone marrow biopsy revealed that B-PLL accounted for 80% of the cellularity in a markedly hypercellular marrow. The bone marrow was diffusely infiltrated with lymphoid cells expressing CD5, CD20, and CD79a, whereas CD10-, CD21-, CD23-, BCL6-, Cyclin D1-, and SOX11-positive cells were absent. A computed tomography scan of the chest, abdomen, and pelvis showed the presence of hepatomegaly and splenomegaly (craniocaudal height, 23 cm).

The patient started receiving idelalisib (150 mg twice daily) and rituximab (375 mg/[m.sup.2]; every two weeks for five doses and then every four weeks for 3 doses). The first two administration instances of rituximab were omitted due to a high tumor burden. Treatment with idelalisib-rituximab led to a rapid resolution (within 2 months) of the lymphocytosis (3.8 x [10.sup.9]/L), accompanied by normalization of the Hb concentration (130 g/L) and platelet count (174 x [10.sup.9]/L) and resolution of the hepatosplenomegaly on CT (Figure 2). After 5 months of therapy, the patient developed grade 3 diarrhea (National Cancer Institute Common Terminology Criteria for Adverse Events v4.0) that resolved after treatment with prednisone (1 mg/kg id) along with discontinuation of idelalisib for 1 month. Thereafter, idelalisib was restarted at a low dose (150 mg daily), but recurrence of the diarrhea during the first week of treatment led to a definitive suspension and a change in therapy. Ibrutinib (420 mg daily) was commenced 2 weeks after idelalisib interruption, and, within the first 2 weeks, the patient developed a transient mild lymphocytosis (15 x [10.sup.9]/L). However, no significant side effects or clinical signs of B-PLL progression were noted, and, after a period of 2 months with ibrutinib, the Hb concentration (156 g/L), lymphocytes (4 x [10.sup.9]/L), and platelets (222 x [10.sup.9]/L) were found to be within the normal range, with no spleen enlargement on physical examination. The patient was treated with ibrutinib until admission for bone marrow transplantation. A reduced-intensity conditioning (RIC) allo-HSCT from a 10/10 HLA-matched unrelated donor was performed. The conditioning regimen included fludarabine (30 mg/[m.sup.2] for 6 consecutive days; days -10 to -5), oral busulfan (4 mg/kg/d for 2 consecutive days; days -6 to -5), and anti-T-lymphocyte globulin (10 mg/kg/d for 4 consecutive days; days -4 to -1) as well as prophylaxis against graft-versus-host disease (GvHD) with mycophenolate mofetil and tacrolimus tapered over 7 months. The regimen was well-tolerated with very mild toxicity and no major transplant-related complications. Six months after the transplant, counts of the lymphocytes, the neutrophils, and platelets and also the Hb concentration were within the normal range and no enlarged organs were detected on CT (Figure 2). In addition, flow cytometry and immunohistochemistry revealed that the bone marrow was free of clonal lymphoid cells. Furthermore, the FISH test carried out to detect leukemic cells harboring a 17p deletion yielded negative results. The patient has been well and in complete remission for 10 months now.

3. Discussion

B-PLL treatment modalities remain to be well-established and little is known about the efficacy of ibrutinib or idelalisibrituximab for this disease. Recently, 5 patients with B-PLL carrying a genetic disruption of TP53 were treated with idelalisib, and sustained remissions (6-10.5 months) were observed in 3 of these patients [15]. Adverse events were noted, namely, grade 2-3 transaminitis (3 patients) and CMV reactivation (1 patient), leading to temporary treatment interruption [15]. Ibrutinib was administered to 2 patients with B-PLL harboring complex cytogenetic abnormalities with aberrations in the TP53 gene. Disease control was achieved with lymphocytosis resolution, accompanied by an improvement in Hb level, platelet count, and splenomegaly. Contrary to CLL, an increase in lymphocytosis was not observed following administration of ibrutinib [16].

Because of the availability of new promising alternative drugs, allogeneic hematopoietic stem cell transplantation (allo-HSCT), regarded as the only curative option for CLL, is now frequently deferred [17]. However, as B-PLL is often characterized by high-risk genetic abnormalities, which partly explains the poor outcomes and short survival times associated with conventional chemoimmunotherapy, suitable patient candidates should be considered for allo-HSCT on first remission.

In the present case, a rapid and meaningful response was observed in TP53-disrupted B-PLL treated sequentially with idelalisib-rituximab and ibrutinib. The response with idelalisib-rituximab was relatively robust and a toxicity profile similar to that already described in CLL was observed. As infusion-related reactions can be markedly decreased if the tumor load is first reduced with an initial course of rituximabfree chemotherapy, 2 cycles of rituximab were omitted [18]. Severe diarrhea, which developed in our patient, is one of the most common adverse events associated with idelalisib (7% of the patients) that prompts dose reduction (34%) and treatment discontinuation (20%) [19]. The clinical presentation of grade 3 diarrhea, after 5 months of therapy with idelalisib, as well as the time to its resolution (interruption of idelalisib and initiation of corticosteroid treatment) was as expected, concurring with another published report [19]. After having suspended idelalisib treatment, our patient started receiving ibrutinib. The disease remained in remission and no adverse events were registered. Ibrutinib is known to promote high response rates, leading to durable remissions in all genetic subsets of CLL patients, and discontinuation of ibrutinib is rarely due to adverse events related to the drug [20, 21]. Interestingly, we have observed an increase in lymphocytosis following the administration of ibrutinib, similar to that seen in CLL. The lymphocytosis, however, does not appear to be associated with an increased risk of progression; nonetheless, these circulating cells may go back to tissue, and disease may become more aggressive following discontinuation of ibrutinib [21].

4. Conclusion

In conclusion, given the poor prognosis of B-PLL and the lack of effective treatment modalities, the findings presented here suggest that both ibrutinib and idelalisib should be considered as upfront therapeutic options for B-PLL and as a bridge to allo-HSCT in eligible patients.

Received 27 March 2017; Revised 6 June 2017; Accepted 2 July 2017; Published 27 July 2017


Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

H. Coelho, M. Badior, and T. Melo jointly wrote and critically reviewed the manuscript.


[1] J. F. Yamamoto and M. T. Goodman, "Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002," Cancer Causes and Control, vol. 19, no. 4, pp. 379-390, 2008.

[2] S. H. Swerdlow, E. Campo, and N. Harris, World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, Lyon, France, 2008.

[3] C. Dearden, "How I treat prolymphocytic leukemia," Blood, vol. 120, no. 3, pp. 538-551, 2012.

[4] F. Ravandi and S. O'Brien, "Chronic lymphoid leukemias other than chronic lymphocytic leukemia: Diagnosis and treatment," Mayo Clinic Proceedings, vol. 80, no. 12, pp. 1660-1674, 2005.

[5] H. Dohner, H. o. AD, J. Thaler et al., "Pentostatin in prolymphocytic leukemia: phase II trial of the european organization for research and treatment of cancer leukemia cooperative study group," Natl Cancer Inst, vol. 85, no. 8, pp. 658-662,1993.

[6] A. Tempescul, J. Feuerbach, J.-C. Ianotto et al., "A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia," Annals of Hematology, vol. 88, no. 1, pp. 85-88, 2009.

[7] K. U. Chow, S. Z. Kim, and N. von Neuhoff, "Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia," European Journal of Haematology, vol. 5, pp. 426-433, 87.

[8] R. Weide, A. Pandorf, J. Heymanns, and H. Koppler, "Bendamustine/Mitoxantrone/Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study," Leukemia and Lymphoma, vol. 45, no. 12, pp. 2445-2449, 2004.

[9] I. Del Giudice, Z. Davis, E. Matutes et al., "IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)," Leukemia, vol. 20, no. 7, pp. 1231-1237, 2006.

[10] P. Shindiapina, J. R. Brown, and A. V. Danilov, "A new hope: Novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53," British Journal of Haematology, vol. 167, no. 2, pp. 149-161, 2014.

[11] S. L. McCune, J. P. Gockerman, and J. O. Moore, "Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia," Leuk Lymphoma, vol. 43, no. 5, pp. 1007-11, 2002.

[12] B. T. Chaar and P. J. Petruska, "Complete response to alemtuzumab in a patient with B prolymphocytic leukemia," American Journal of Hematology, vol. 82, no. 5, p. 417, 2007

[13] A. Wiestner, "The role of b-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia," Haematologica, vol. 100, no. 12, pp. 1495-1507, 2015.

[14] P. Jain, MJ. Keating, and W. Wierda, "Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL)," Clinical Cancer Research, vol. 23, no. 9, pp. 2154-2158, 2017

[15] T. A. Eyre, C. P. Fox, and P. Shankara, "Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia," Br J Haematol, vol. 177, no. 3, pp. 486-91, 2017.

[16] M. J. Gordon, P. W. Raess, and K. Young, "Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia," British Journal of Haematology, 2016.

[17] F. McClanahan and J. Gribben, "New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective," Clinical Advances in Hematology & Oncology, vol. 13, no. 9, pp. 586-594, 2015.

[18] P. J. Bugelski, R. Achuthanandam, and R. J. Capocasale, "Monoclonal antibody- induced cytokine-release syndrome," Expert Review of Clinical Immunology, vol. 5, no. 5, pp. 499-521, 2009.

[19] S. E. Coutre, J. C. Barrientos, and J. R. Brown, "Management of adverse events associated with idelalisib treatment: expert panel opinion," Leuk Lymphoma, vol. 56, no. 10, pp. 2779-2786, 2015.

[20] S. Molica, "The clinical safety of ibrutinib in chronic lymphocytic leukemia," Expert Opinion on Drug Safety, vol. 14, no. 10, pp. 1621-1629, 2015.

[21] F. Forconi, "Three years of ibrutinib in CLL," Blood, vol. 125, no. 16, pp. 2455-2456, 2015.

H. Coelho, M. Badior, and T. Melo

Servifo de Hematologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova Gaia, Portugal Correspondence should be addressed to H. Coelho;

Academic Editor: Tatsuharu Ohno

Caption: FIGURE 1: Peripheral blood smear. The lymphoid cells are of intermediate to large size with a prominent nucleolus and cytoplasm protrusions (Wright-Giemsa, x1000).

Caption: FIGURE 2: Response to idelalisib-rituximab started on day 0, ibrutinib started in month 6, and reduced- intensity conditioning allo-HSCT was performed in month 8. (a) Absolute lymphocyte count. (b) Platelet count, hemoglobin concentration, and spleen size (measured by CT scan/longest diameter).
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Case Report
Author:Coelho, H.; Badior, M.; Melo, T.
Publication:Case Reports in Hematology
Article Type:Clinical report
Date:Jan 1, 2017
Previous Article:Extensive Intracardiac and Deep Venous Thromboses in a Young Woman with Heparin-Induced Thrombocytopenia and May-Thurner Syndrome.
Next Article:Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom's Macroglobulinemia.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |